Abstract:Objective: To investigate the prognostic significance of different IDH mutations and accompanying gene mutations in patients with non-M(3) acute myeloid leukemia (AML) . Methods: Second-generation sequencing was performed to detect the mutations of 22 genes in 389 patients with AML in the First Affiliated Hospital of Zhengzhou University from June 2016 to December 2018, and Kaplan-Meier and Cox regression models were used to analyze the prognostic factors. Results: The mutation frequency of IDH1 and IDH2 was 6.2% and 8.7% , respectively, in all patients without co-mutation. The IDH2 mutant group had an older age, higher proportion of bone marrow primitive cells, more common normal karyotype, and more common RUNX1 and SRSF2 mutations compared with IDH2 wild-type group. Univariate analysis of variance showed that the median OS and PFS of IDH1 mutation group were significantly shorter than those of the wild-type group (P<0.05) . IDH2 mutation as a single variable and IDH2R140 mutation had no significant effect on the prognosis, while different mutation sites had different effects. Compared with the IDH2 wild-type group, the IDH2R172 mutation group had lower complete remission (CR) rate and shorter median OS and PFS (P<0.05) . In patients with normal karyotypes or aged ≥50 years, IDH2 mutation as a single variable had no significant effect on the prognosis, IDH1 mutation and IDH2R172 mutation were associated with poor OS and PFS (P<0.05) , and IDH2R140 mutation had no significant effect on OS and PFS. Approximately 74.1% (43/58) of patients with IDH mutation simultaneously carried other gene mutations; however, the number of accompanying gene mutations had no significant effect on the prognosis. Among 58 patients with IDH mutation, the CR rate of patients with NPM1 mutation was significantly higher than that of patients in the NPM1 wild-type group (81.8% vs 36.4% , P=0.014) , the median OS in patients with DNMT3A mutation was lower than that of patients with DNMT3A wild type [4.0 months (95% CI 3.8-4.2) vs 6.3 months (95% CI 2.4-10.2) , P=0.041) ]. Multivariate analysis showed that age ≥60 years and white blood cell count ≥100×10(9)/L were independent risk factors for OS and PFS, while CR after two courses of treatment and hematopoietic stem cell transplantation were independent prognostic favorable factors for OS and PFS. Conclusion: In patients with AML (non-M(3)) , IDH gene mutations often coexisted with other gene mutations, and different subtypes and accompanying gene mutations of IDH have different prognostic significance.

Some Novel Features of IDH1-mutated Acute Myeloid Leukemia Revealed in Chinese Patients

High IDH1 Expression is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia.

Prognostic Significance of IDH1 and IDH2 Mutations in Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia

Prognostic Significance of IDH1 Mutations in Acute Myeloid Leukemia: a Meta-Analysis.

[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].

Expression and Clinical Significance of ID1 Gene in Acute Myeloid Leukemia

IDH1 and IDH2 Mutations Are Frequent in Chinese Patients with Acute Myeloid Leukemia but Rare in Other Types of Hematological Disorders.

[Analysis of IDH1 and IDH2 Mutations in Patients with Acute Myeloid Leukemia].

Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia

Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: a Retrospective Cohort Study and Meta-Analysis.

FLT3-ITD As a Prognostic Factor for Chinese Patients with Acute Myeloid Leukemia

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

The Clinical Impact of IKZF1 Mutation in Acute Myeloid Leukemia

FLT3 and NPM1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Normal Cytogenetics

New Insights into the Clinical Characteristics of SETD2-mutated Acute Myeloid Leukaemia.

Prognostic Significance of Huntingtin Interacting Protein 1 Expression on Patients with Acute Myeloid Leukemia

Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3A mut .

IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis

Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.

[Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia]

P89.07 A Large-Scale Survey of IDH1/2 Mutation in Chinese Patients with NSCLC